| 000 | 02497cam a2200277 4500500 | ||
|---|---|---|---|
| 005 | 20250121154613.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aSommer, Rachel _eauthor |
| 700 | 1 | 0 |
_a da Silva, Neuza _eauthor |
| 700 | 1 | 0 |
_a Langenbruch, Anna _eauthor |
| 700 | 1 | 0 |
_a Maurer, Marcus _eauthor |
| 700 | 1 | 0 |
_a Staubach-Renz, Petra _eauthor |
| 700 | 1 | 0 |
_a Augustin, Matthias _eauthor |
| 245 | 0 | 0 | _aCharacteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria |
| 260 | _c2020. | ||
| 500 | _a21 | ||
| 520 | _aBackground: Treatment of chronic spontaneous urticaria (CSU) is founded on evidence-based guidelines. However, specific patient needs and benefits of therapy have not been outlined at the guideline level. Objectives: The aim of this study was to characterise the specific needs and treatment goals in chronic spontaneous urticaria from the patient's perspective. Materials and Methods: This cross-sectional study was conducted in four German outpatient dermatology clinics. Patient needs and potential therapy goals were determined with the validated Patient Needs Questionnaire (PNQ) using a specific version for chronic urticaria. Further instruments to characterise the link between patient needs and disease burden were disease-specific (CU-Q2oL), skin-generic (DLQI) and health-generic (EQ VAS) scales. Results: Data from 103 patients were analysed (age: 43.92 ± 14.96 years; 71.4% female). Among the most important therapeutic goals were the absence of visible skin lesions (92.3% important/very important), to be free of itching (91.5%) and the desire to be healed of all skin defects (89.5%). All 26 items were found to be quite important/very important by at least 30% of the respondents. Specific profiles of patient needs were found to be related to sex and disease duration. Conclusion: Innovative drugs and patient-centred individualised treatment may increase overall benefits. Regardless of the treatment chosen, shared decision making in the management of the disease should be a goal. | ||
| 690 | _ahealth-related quality of life | ||
| 690 | _apatient preferences | ||
| 690 | _apatient-reported outcome measures | ||
| 690 | _aquality of life | ||
| 690 | _across-sectional study | ||
| 786 | 0 | _nEuropean Journal of Dermatology | 30 | 3 | 2020-05-01 | p. 259-266 | 1167-1122 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/revue-european-journal-of-dermatology-2020-3-page-259?lang=en&redirect-ssocas=7080 |
| 999 |
_c602744 _d602744 |
||